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Squamous cell carcinomaMedical imaging by use of immunotargeting generally relies on a labeled molecule binding to a speciﬁc target
on the cell surface. It is important to utilize both cell-based and time-resolved binding assays in order to
understand the properties of such molecular interactions in a relevant setting.
In this report we describe the detailed characterization of the interaction properties for AbD15179, a
promising CD44v6-targeting antibody fragment for radio-immunotargeting. Inﬂuence of labeling and cell-
line model on the protein interaction kinetics was assessed using three different labeling approaches
(111In, 125I and FITC) on three different squamous carcinoma cell lines. Interactions were measured using
time-resolved assays on living cells, and further analyzed with Interaction Map®.
Results demonstrated a general biphasic appearance of a high- and a low-afﬁnity binding event in all cases.
The relative contribution from these two interactions differed between conjugates. For 125I-Fab, the
population of low-afﬁnity binders could be signiﬁcantly increased by extending the chloramine T exposure
during labeling, whereas the 111In-labeling predominantly resulted in a high-afﬁnity interaction. Interactions
were also shown to be cell line dependent, with e.g. SCC-25 cells generally mediating a faster dissociation of
conjugates compared to the other cell lines.
In conclusion, we report both cell line dependent and labeling associated variations in interaction kinetics for
AbD15179 binding to CD44v6. This has implications for cell-based kinetic assays and applications based on
labeled conjugates in general, as well as in a clinical setting, where each individual tumor may create different
kinetic proﬁles for the same conjugate.Sciences, Rudbeck Laboratory,
+46 18 4713432.
r).
l rights reserved.© 2014 Elsevier Inc. All rights reserved.1. Introduction
The ability of antibodies to speciﬁcally recognize molecular
structures is used for many purposes in medicine. Recent develop-
ments in ﬁelds such as cancer biology and antigen screening have
facilitated the rational design of targeted pharmaceuticals, with
monoclonal antibodies (MAbs) forming the most rapidly expanding
category.More than 25% of all pharmacological agents currently under
development are antibody based, including several engineered MAb
fragments and protein scaffolds [1,2].Medical imaging in cancer by use
of immunotargeting generally relies on a labeledmolecule binding to a
speciﬁc target on the tumor,where the interactions between agent and
target take place in the complex setting of cell surfaces. It is therefore
important to understand the properties of these interactions in their
working environment, so that they can be utilized in the best manner.
A targeting molecule may for example bind differently to a monomer
or a dimerized receptor [3,4], or interact in different ways with thewild type and a mutated version of an antigen, hence promoting
different actions depending on what type of interaction is dominating
in that particular cell. Furthermore, detailed characterizations of the
complex kinetics of agent and antigen interactionsmay clarify if one or
several interactions are taking place, which of these trigger the desired
effect, and if these interactions are altered when the agent is labeled.
Such studies should be performed at an early stage, in order to help
identify suitable patient sub-populations for clinical trials, or ﬁnding
the most suitable labeling approach.
There are several assays suitable for the analysis of molecular
interactions available today. Flow cytometry [5] and immunoﬂuores-
cence [6] assays are two typical examples that can be used on living or
ﬁxated cells, both being end-point measurements with relatively high
throughput when automated. Recently, cell-based time-resolved
assays have been developed [3,7]. By introducing time into the
binding assay, the information output is increased and the throughput
is decreased. Such assays are therefore suitable for obtaining a more
detailed understanding of an interaction rather than screening for all
molecules that bind. Analysis of such real-time binding data can be
performed with Interaction Map®. This is a mathematical method
that translates time-resolved binding curves into its separate
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neity as a map.
Even though a diverse selection of reﬁned agents suitable for tumor
imaging exists today, there is a lack of appropriate binders in the ﬁeld
of head and neck cancer. The vast majority (N90%) of head and neck
cancers are squamous cell carcinomas (HNSCC), which makes it
attractive to target tumor-associated antigens preferentially
expressed by those malignant cells [8,9]. Targeting molecules binding
to such antigens may therefore be utilized as tools for radioimmuno-
diagnostics, a tumor speciﬁc medical imaging method for early
detection. This technique combines the high sensitivity and resolution
of a PET or SPECT camera with the tumor speciﬁcity of an antibody or
antibody fragment, and may improve the management of patients
with HNSCC. Attempts to screen for speciﬁc HNSCC targets have
identiﬁed CD44v6 as one promising target antigen [10]. This is an
isoform of the cell adhesion molecule CD44, a complex family of
molecules that arise from alternative splicing and post-translational
modiﬁcations of one gene [11,12]. The CD44v6 antigen itself is present
in several isoforms, has been connected to tumor formation, invasion
and metastasis, and high and homogeneous expression of v6-positive
isoforms has been reported in a vast majority of HNSCC specimens
[10–12]. CD44v6 has also been associated with other cancer forms, for
example non-Hodgkin’s lymphoma, colorectal-, cervical- and gastric
cancer [8,13], which establishes its potential as a target even further.
To facilitate improved targeting of CD44v6, we have previously
selected and characterized novel fully human CD44v6-binding Fab
fragments and demonstrated their promise as molecular targeting
probes in vitro [14]. To our knowledge, our Fab fragments represent
the best-characterized recombinant antibody fragments against
CD44v6, and are the ﬁrst of fully human origin to be reported. One
main candidate, AbD15179, demonstrated suitable kinetic properties
for immunotargeting and was selected for further characterization of
binding speciﬁcity and kinetic parameters of differently labeled
conjugates, aiming to achieve a more detailed understanding of
interaction events and their relevance for molecular imaging.
In this report we describe the detailed investigation of interaction
characteristics for the CD44v6-targeting antibody fragment
AbD15179. The aim was to investigate if cell-based real-time
measurements and interaction analysis could provide useful infor-
mation on the inﬂuence of labeling and cell line model on protein
interaction kinetics. Several different labeling approaches were
assessed, including different speciﬁc activities, labeling conditions,
radionuclides and labeling techniques, on SCC cell lines with varying
CD44v6 expression. This was done using time resolved assays, rather
than end-point assays, in order to collect as much information as
possible. The characterization was made on living cells rather than
with immobilized antigens in order to mimic an in vivo setting, and
Interaction Map was used to analyze the real-time data in order to




The HNSCC human cell lines SCC-25 (obtained from American
Type Culture Collection) and H314 (obtained from European
Collection of Cell Cultures) were cultured in a one-to-one mixture of
Ham’s F12 and Dulbecco’s Modiﬁed Eagle Medium (DMEM), supple-
mented with 10% foetal calf serum, 2 mM L-glutamine, and antibiotics
(100 IU penicillin and 100 μg/ml streptomycin). The SCC cell line A431
(obtained from American Type Culture Collection) was cultured in
Ham’s F10, with the same supplements. As a negative control, the
CD44v6-negative human MDA-MB-231 breast cancer cell line
(obtained from American Type Culture Collection) was used. It was
cultured in DMEM, with the same supplements as above.Cells were incubated at 37°C in an atmosphere containing
humidiﬁed air with 5% CO2.
For antigen density experiments, dishes were seeded with
approximately 5*104 cells/well. For LigandTracer studies, cells were
seeded in a local part on a 10-cm cell dish (#150350; Nunc) and
allowed to adhere ﬁrmly to the plastics prior to the addition of fresh
medium. Experiments were conducted 2–3 days after seeding.
2.2. Antibodies and antibody fragments
The anti CD44v6 cMAb U36, kindly supplied by Dr. van Dongen,
recognizes the CD44v6 antigen, located on the outer cell surface.
Selection andproductionof theantibodyhavebeendescribedpreviously
[15,16]. The antibody was supplied in citrate buffer, and separated upon
arrival by size-exclusion chromatography on a NAP-5 column (Amer-
sham Biosciences, Uppsala, Sweden) pre-equilibrated with puriﬁed
(MilliQ) water. It was then freeze-dried and stored at−20 °C.
The anti CD44v6 Fab-fragment AbD15179 was supplied from AbD
Serotec. Selection and production of the antibody have been described
previously [17]. The Fab fragmentwas supplied in 3× PBS, and stored in
−80 °C. Fragments for 111In-labeling were separated by size-exclusion
chromatography on a NAP-5 column (Amersham Biosciences, Uppsala,
Sweden) pre-equilibrated with puriﬁed (MilliQ) water. It was then
freeze-dried and stored at−20 °C before use.
2.3. Labeling of antibodies and antibody fragments
Antibody fragment AbD15179 and cMAbU36were labeledwith 125I
(PerkinElmer, Waltham, MA, USA) using direct chloramine T labeling
[18] (Sigma-Aldrich), previously described by Nilvebrant et al. [17]. In a
ﬁrst set of studies, AbD15179 was labeled using different amounts of
chloramine T (CAT) exposure and speciﬁc activity of 125I, in order to
assess the inﬂuence of these factors on binding properties. Brieﬂy, a
stock solution of 125I (2 MBq for a) “Mildest conditions" and b) “High
CAT exposure", and 20 MBq for c) “High speciﬁc activity") was mixed
with 80 μl PBS and the Fab-fragment (35 μl, 0.72 mg/mL in PBS) was
added. The reaction was initiated by addition of CAT (4 mg/ml, Sigma
Aldrich) in water (10 μl CAT for a) and c), whereas b) received 20 μl
CAT), and was quenched after incubation on ice (2 min for a) and c),
whereas b) was incubated for 10 min) by addition of sodium
metabisulphite (Merck) (4 mg/ml) in water (20 μl for a) and c),
whereas b) received 40 μl). Each labeled protein was separated from
non-reacted 125I and low-molecular-weight reaction components on a
NAP-5 column pre-equilibrated with PBS. For succeeding 125I-labelings
of AbD15179 and cMAb U36, the following labeling conditions were
chosen: 7.5 MBq 125I, 10 μl of CAT (4 mg/ml) and 5 min incubation,
followed by quenching of the reaction using 20 μl sodium metabisul-
phite and separation on a NAP-5 column. 125I-labeled AbD15179 and
cMAb U36 will be referred to as 125I-Fab and 125I-U36, respectively.
Labeling of antibody fragment AbD15179 with 111In (Mallinckrodt
Medical B.V.) was made using CHX-A”-DTPA labeling as described
previously by Nestor et al. [19]. In short, to 15 μl AbD15179 solution (5
mg/ml in borate buffer, pH 9), 4.1 μl of CHX-A”-DTPA solution (1mg/ml
in borate buffer, 0.07 M, pH 9) was added, corresponding to a chelator-
to-AbD15179 molar ratio of 5:1. The reaction mixture was incubated
over night at room temperature, and the conjugated antibodywas then
separated from free CHX-A”-DTPA using a NAP-5 column equilibrated
with acetate buffer (0.2 M, pH 5.5). Approximately 10 MBq of 111In in
acetate buffer was then added to the conjugated AbD15179, and the
reaction mixture was allowed to incubate during 30 min at room
temperature. Labeled antibody was then separated from non-reacted
radionuclide and low-molecular-weight reaction components by using
a NAP-5 column pre-equilibrated with PBS. 111In-labeled AbD15179
will be referred to as 111In-Fab.
Labeling of antibody fragment AbD15179 with ﬂuorescein isothio-
cyanate (FITC; Pierce) was made according to the instruction of the
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80 μl borate buffer (pH 9), and 4 μl of FITC solution was added (1mg/
ml in DMSO). The solution was mixed, and incubated in 37 °C for 90
min. Labeled protein was then separated from non-reacted FITC and
low-molecular-weight reaction components on a NAP-5 column pre-
equilibrated with PBS. FITC-labeled AbD15179 will be referred to as
FITC-Fab.
To determine the extent of aggregation, 125I-, 111In- and FITC-
labeled AbD15179 Fab fragments were run in triplicates on Native-
PAGE™ Novex® 4%–16% Bis-Tris gels (Life Technologies, USA)
according to manufacturer’s instructions. NativeMARK™ Unstained
Protein Standard (Life Technologies, USA) was used as size control.
125I-Fab and 111In-Fab conjugates were measured on a Cyclone
Storage Phosphor System followed by data analysis in the OptiQuant
image analysis software. FITC-Fab conjugate bands were visualized
and captured with a CCD camera (SuperCCD HR, Fujiﬁlm, Japan) and
imageswere analyzedwith the ImageJ software (National Institutes of
Health, Bethesda, Maryland). To determine the purity and stability of
the labeled antibody fragments over time, instant thin-layer chroma-
tography (ITLC) was performed on 125I and 111In-labeled conjugates.
Samples taken immediately, as well as 48 h after the labeling
procedure, were analyzed. Approximately one microliter of the
conjugate was placed on a chromatography strip (Biodex) and put
into a "running buffer" (70% acetone or 0.2 M citric acid for 125I
and 111In respectively), followed by measurements on a Cyclone
Storage Phosphor System. Data were analyzed using the OptiQuant
image analysis software.
2.4. CD44v6 antigen density
CD44v6 cell surface expression assays were performed for H314
and MDA-MB-231 cells, and have been determined previously by us
for SCC-25 and A431 cells [20]. The number of CD44v6 antigens per
cell was calculated using saturation curves with a ﬁxed amount of
cells and different concentrations of radiolabeled antibody. Saturation
assays on cultured cells were performed using radioiodinated cMAb
U36 for all cell lines. Wells seeded with approximately 5*104 cells
were ﬁrst washed with 1 mL serum free medium. A 100-times molar
excess of unlabeled antibody was added to some of the wells per data
point for nonspeciﬁc binding correction. Concentrations varying
between 0.1 and 100 nM of 125I-labeled antibody in supplemented
cell culture medium were added to wells. Cells were then incubated
on ice for 6 h in an atmosphere containing humidiﬁed air with 5% CO2.
The incubation medium was removed, and the wells were washed
with serum free medium. The cells were then detached with trypsin-
EDTA solution for 10 min at 37 °C, and resuspended in 1 mL complete
culture medium. Cell counting was performed on 0.5 mL of the
suspension, and radioactivity measurements were performed on the
remaining solution in a gamma well-counter. Data from saturation
curves were analyzed in GraphPad Prism, using non-linear regression
analysis (one site binding) to calculate Bmax.
2.5. Real-time binding measurements on SCC cells
In order to assess the impact of speciﬁc activity and chloramine T
exposure on binding properties AbD15179 was ﬁrst labeled using
different amounts of 125I and chloramine T exposure as described
above, and evaluated in room temperature with LigandTracer Grey
(Ridgeview Instruments AB, Uppsala, Sweden) using A431 cells.
Binding traces using three subsequent concentrations of Fab frag-
ments were collected, followed by a dissociation measurement. In
brief, radiolabeled conjugates were added to the dish at approxi-
mately 0, 2, and 4 h after measurement start, corresponding to
concentrations of 10, 30 and 90 nM, respectively. At 6 h, dissociation
measurements were initiated by removing Fab-containing mediumand adding 3 ml of fresh medium. Binding traces were then followed
for an additional 16 h.
Furthermore, afﬁnity estimations of the interaction between
labeled Fab fragments and the three SCC cell lines SCC-25, H314 and
A431 were then performed, in order to evaluate the impact of label
and cell line model on real-time binding interactions. LigandTracer
Grey was used for 125I- Fab, LigandTracer Yellow for 111In- Fab and
LigandTracer Green for FITC-Fab, using the same conditions as for
LigandTracer Grey studies described above.
2.6. Interaction Map analysis
In order to display interaction characteristics and heterogeneity,
Interaction Map was used. Data from real-time LigandTracer mea-
surements of 125I-Fab, 111In-Fab, and FITC-Fab binding to H314, SCC-
25 and A431 cells were analyzed in TraceDrawer 1.4 using the
Interaction Map kinetic analysis method, as described previously
[3,17,21,22]. In short, Interaction Map translates measured real-time
binding curves to a three-dimensional map that describes the
heterogeneous interaction, providing a broader view on the concept
of speciﬁcity. The results are depicted in a modiﬁed on–off map [23],
where each peak corresponds to one type of interaction. The
coordinates of the peak areas represent the kinetic properties (the
association rate constant, ka, and the dissociation rate constant, kd),
whereas the color indicates the contribution or weight factor. The
overall contribution over a deﬁned area in the map can be integrated
to estimate proportions of different interactions to a measured curve.
Analyses of variance from InteractionMap data weremade using One-
way ANOVA followed by Tukey's Multiple Comparison Test, and were
considered signiﬁcant if P b 0.05.
3. Results
3.1. Labeling
For the ﬁrst set of 125I experiments, in which AbD15179 antibody
fragments were labeled using varying amounts of 125I (I.e. 2 MBq for
a) “Mildest conditions" and b) “High CAT exposure", and 20MBq for c)
“High speciﬁc activity") and CAT exposure (2min exposure with 40 μg
for a) and c), whereas b) received 10 min exposure with 80 μg CAT),
labeling yields were 50%–51%, 57%–59% and 65%–69% for a) b) and c)
respectively, resulting in speciﬁc activities of 1.9–2.2 MBq/nmol for a)
and b), and 24–26 MBq/mol for c). Purity as determined by ITLC was
94%–100%. As expected, direct labeling using CAT resulted in high
aggregation, where consequently the high CAT exposure resulted in
the lowest fraction of monomers (2%–4% monomers for c), compared
to 7%–11% for both the a) and b) conditions). For direct CAT labeling
with the intermediate conditions used throughout the rest of the
studies (5 min incubation with 40 μg CAT and 7.5 MBq 125I) labeling
yields ranged from 55% to 90%, typically resulting in speciﬁc activities
around 14 MBq/nmol. The purity of the 125I-labeled proteins was
between 94% and 100% according to ITLC analysis, and relative
amounts of monomers were 5%–12%.
For 111In-labeling of AbD15179, yields ranged between 63% and
98%, and purity was between 95% and 100% according to ITLC
analysis, typically resulting in speciﬁc activities around 4 MBq/nmol,
and 42%–48% monomers. FITC-labeling of AbD15179 resulted in
28%–38% monomers. Purity of radiolabeled conjugates stored in PBS
was re-analyzed 48 h after labeling, and was unchanged according to
ITLC analysis.
3.2. Antigen density
Cells were quantiﬁed for CD44v6 expression using radioiodinated
cMAb U36 in saturation assays. In H314 cells, antigen expression was
determined to be 0.65*106 ± 0.04*106 (standard error) antigens per
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and SCC-25 cells were previously characterized for CD44v6 antigen
expression in the same way, demonstrating 3*106 ± 0.07*106 and 1.7
*106 ± 0.03 *106 antigens per cell, respectively [20].
3.3. Speciﬁcity of labeled fragments
Real time interaction analyses of 125I-Fab and 111In-Fab in MDA-
MB-231, H314, SCC-25, and A431 cells demonstrated a difference in
signal detection (i.e. counts per cell corrected for cell number) for the
different cell-lines, in line with the number of CD44v6 antigens
present on the cells. I.e. no/very low signal was detected forMDA cells,
intermediate signal was detected for H314 and SCC-25 cells, whereas
A431 cells resulted in the highest signal (data not shown). This
indicates that the conjugates bind speciﬁcally to the antigen.
3.4. Impact of speciﬁc activity and chloramine T exposure on
125I-labeled fragments
In order to investigate if real-time measurements and Interaction
Map analysis could provide useful information on the impact of high
speciﬁc activity or CAT exposure onmolecular interactions, AbD15179
labeled with 125I using different amounts of speciﬁc activity and CAT
exposure was evaluated using LigandTracer (Fig. 1a) and Interaction
Map (Fig. 1b and c) in A431 cells. LigandTracer results demonstrated a
clear effect of CAT exposure on the dissociation phase, whereas
speciﬁc activity only had a minor effect (Fig. 1a). Results were
conﬁrmed by Interaction Map analysis, demonstrating a signiﬁcantly
reduced high afﬁnity population (P b 0.001 compared to mild
conditions, and P b 0.01 compared to high 125I conditions) for these
conjugates, approximately reduced by 30% from conjugates exposed
to the mildest labeling conditions (Fig. 1b). The low afﬁnityFig. 1. Impact of high chloramine T exposure and high 125I speciﬁc activity, compared to mil
measurements of the interactions, demonstrating a faster dissociation phase for the conju
speciﬁc activity of 125I (yellow) and the conjugate with both low chloramine T exposure a
LigandTracer data of the weight of the high afﬁnity peak, normalized to the conjugates expo
followed by Tukey's Multiple Comparison Test, and were considered signiﬁcant if P b 0.0
inﬂuenced by labeling conditions. Conjugates with high chloramine T exposure demonstrate
** compared to high 125I conditions), approximately reduced by 30% from conjugates expose
a tendency of reduced high afﬁnity population, although not statistically signiﬁcant. Error b
analyses of the impact of high chloramine T ("High CAT") exposure and high speciﬁc activity
of 125I-AbD15179 binding to A431 cells. The "High CAT" conjugates demonstrated a clear sh
population (right population).population was increased correspondingly (Fig. 1c). The conjugate
with high speciﬁc activity displayed a tendency of a slightly reduced
high afﬁnity population, although not statistically signiﬁcant (Fig. 1b).
KD of the high and low afﬁnity populations was not signiﬁcantly
altered with these treatments (data not shown).
3.5. Effect of labeling method and cell line model on AbD15179-CD44v6
interactions
Representative binding curves, normalized to 100% at maximum
binding level, for all three AbD15179 conjugates labeled with
FITC, 125I or 111In categorized by cell line (H314, SCC-25, and
A431) can be seen in Fig. 2a. The association is shown during three
concentrations (10, 30, 90 nM, 2 h for each concentration) followed by
a dissociation phase for at least 16 h. The conjugates followed similar
patterns in all three cell lines, with a primarily faster on-rate for FITC-
Fab, a faster off-rate for 125I-Fab, and a slower off-rate for 111In-Fab.
For example, after 16 h of dissociation in A431 cells approximately
75% of the 111In-labeled conjugate remained bound, whereas cells
retained 55% and 60% of the 125I-Fab and FITC-Fab, respectively.
Not only the labeling method, but also the choice of cell line model
inﬂuenced the binding pattern of the conjugates. In Fig. 2b, binding
curves in H314, SCC-25, and A431 cells can be seen, categorized by
labeling method. Although each conjugate generally displayed similar
binding patterns in the different cell lines, clear differences in
behavior could be seen between cell lines. Dissociation was generally
slower in A431 cells than in SCC-25 cells. For example, at 16 h of
dissociation twice the amount of the 111In-Fab remained on A431 cells
compared to SCC-25 cells.
Representative results from Interaction Map calculations can be
seen in Fig. 3. Results conﬁrmed and complemented the LigandTracer
analyses. The Fab interactions with cells generally consisted of twoder labeling conditions, of 125I-AbD15179 in A431 cells. a) Representative LigandTracer
gate highly exposed to chloramine T (red) compared to the conjugates with higher
nd low speciﬁc activity (green). b) Summary of Interaction Map calculations from all
sed to the mildest conditions. Analyses of variance were made using One-way ANOVA
5. The ratios between high- and low afﬁnity interactions in A431 cells were clearly
d a signiﬁcantly reduced high afﬁnity population (*** compared to mild conditions, and
d to the mildest labeling conditions. The conjugate with high speciﬁc activity displayed
ars represent standard deviation. N = 4. c) Representative ﬁgures of Interaction Map
("High 125I") compared to low chloramine T exposure and low speciﬁc activity ("Mild")
ift in interactions, from the high afﬁnity population (left population) to the low afﬁnity
Fig. 2. Representative LigandTracer measurements, normalized to 100% at maximum binding level, of differently labeled Fab-fragment AbD15179 in three different SCC cell lines,
grouped by cell line or labeled conjugate. a) Conjugate-dependent binding behavior: comparison of the binding patterns of the differently labeled conjugates, shown for three
different cell lines. Binding curves show AbD15179 labeled with FITC (green), 125I (black), and 111In (orange) in the cell lines H314 (left), SCC-25 (middle) and A431 (right). b) Cell
line dependent binding behavior: comparison of the binding behavior of each conjugate for three different cell lines. Binding curves show AbD15179 labeled with 125I (left), 111In
(middle), and FITC (right) in the SCC cell lines A431 (red), SCC-25 (blue) and H314 (green). LigandTracer measurements were repeated at least three times for all conjugates and cell
line combinations.
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afﬁnity” population. The 111In-Fab displayed a larger contribution
from the high afﬁnity peak in all three cell lines, whereas FITC-Fab
and 125I-Fab demonstrated a lower contribution from this interac-
tion (further assessed below). A summary of Interaction Map data
from all runs in terms of KD, peak weight (%), ka, and kd of the high
afﬁnity interaction can be seen in Fig. 4. Results demonstrated a
signiﬁcantly higher contribution from the high afﬁnity peak for 111In-
Fab compared to 125I-Fab in H314 and A431 cells, whereas the choice
of cell line did not seem to inﬂuence the weight of the populations
(Fig. 4a). Also KD of the high afﬁnity peak appeared to be mainly
conjugate dependent. A trend of higher KD for 111In-Fab and lower
for 125I-Fab could be seen for all three cell lines, although this was
only statistically signiﬁcant in SCC-25 cells (Fig. 4b). However, when
also considering ka and kd, another pattern more dependent on cell
line than on choice of conjugate appeared. For 111In-Fab and 125I-
Fab conjugates, the SCC-25 cell line demonstrated a signiﬁcantly
increased dissociation rate constant (kd) compared to the other two
cell lines. The same trend could be seen for the association rate
constant (ka), but was not statistically signiﬁcant (Fig. 4c and d).
4. Discussion
This report describes the variability of the Fab fragment AbD15179
binding to CD44v6 when different labeling methods and hosting
cell lines are used, and demonstrates the vast amount of informa-
tion that is gained using cell-based time-resolved binding analysis.
A clear variation in interactionparameterswas observedboth between
the different labeling methods and the cell lines. This heterogeneous
interaction information could be of aid for quality control of a labeled
conjugate, selection of suitable labeling techniques or radioconjugates,
or for assessment of a suitable cell-line for further characterizations.
When comparing the real-time measurements between different
cell lines in this study, it is clear that the choice of cell line inﬂuences
AbD15179-CD44v6 binding events (Fig. 2b). Generally, differences in
dissociation rates were most apparent, whereas KD and the relative
contribution from high- and low afﬁnity interactions did not differ
signiﬁcantly between cell lines for each label. In this study, we usedthree different squamous cell carcinoma cell lines with different
CD44v6 density, with A431 cells expressing the highest and H314 the
lowest amount of antigens per cell. It was however the intermediate
CD44v6-expressing cell line SCC-25 that generally deviated the most
in binding behavior, with a faster dissociation from cells (Fig. 2) and
consequently with higher dissociation rate constants than the other
two cell lines for all conjugates (Fig. 4c). Furthermore, the conjugates
demonstrated considerably slower dissociation rates in A431 cells
than in SCC-25 cells (Figs. 2 and 4c). The underlying reason for this
difference is unknown. One explanation could be the higher CD44v6
density of A431 cells compared to SCC-25 and H314 cells. However,
this would suggest that the H314 cell line with the lowest CD44v6
density would display the fastest dissociation rate, which was not the
case. One potential origin of the observed cell line dependent
differences could be the various isoforms in which CD44v6 is present
[8]. Consequently, one could speculate that if the cells display
different CD44v6-containing isoforms, this could cause conforma-
tional changes of the antigen large enough to be readily detectable as
variations of the Fab fragment binding. Barta and co-authors recently
reported that protein interactions with HER-family receptors can have
different characteristics depending on the hosting cell line [5]. The
general cell context dependency for protein–receptor interactions
cannot be estimated until many more systems have been character-
ized, but clearly it is not limited to HER-family receptors. Hence, also
for CD44v6 it is important to refer to the measured afﬁnity for a
protein–receptor interaction together with the hosting cell line.
Moreover, we have demonstrated the importance to characterize
protein interactions also after labeling. Many reagents used in cell-
based assays are labeled with a ﬂuorescent or radioactive moiety to
become detectable. The inﬂuence of the labeling procedure on the
binding assay result is rarely discussed, but can potentially have large
impact on the characteristics of a molecular interaction. The use of
different linkers and chelates may inﬂuence binding, and alter overall
charge, size, and lipophilicity of the compound, which may result in a
conjugate behaving differently from the original compound both in
vitro and in vivo [24–26]. Furthermore, there is often an abundance of
tyrosine residues in the complementarity determining regions (CDR)
of antibodies. This may result in decreased immunoreactivity of the
Fig. 3. Representative ﬁgures of Interaction Map analyses in H314 cells (top row), SCC-25 cells (middle row) and A431 cells (bottom row) for AbD15179 labeled with 125I (left
column), 111In (middle column) or FITC (right column). Results demonstrated a general biphasic appearance of a high- and a low-afﬁnity interaction event in all cases. However, the
relative contribution from the two interactions differed between conjugates. Whereas the 125I- and FITC-labeled fragments produced clear biphasic interactions, the 111In-labeled
fragment was dominated by the high-afﬁnity interaction. Furthermore, kd of the high-afﬁnity interaction was generally lowest in A431 cells, and highest in SCC-25, resulting in a
slower off-rate of conjugates in A431 cells.
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radiohalogenation of the tyrosine residues is used [27]. Moreover, the
harsh oxidative environment caused by chloramine T might also
decrease the binding capacity of conjugates and increase aggregation
[28]. Therefore, we ﬁrst assessed the effects of high chloramine T
exposure and high speciﬁc activity in A431 cells (Fig. 1). Results
showed clearly that a high chloramine T exposure signiﬁcantly
increased the low afﬁnity population, while speciﬁc activity only
had a minor effect. This effect correlated with the decrease of
monomers and the amount of aggregates formed during labeling.
Furthermore, when comparing the results from different labeling
methods in this study, the interaction had different proﬁles depending
on labeling chemistry. Here, FITC and 111In were both attached to
primary amine groups (N-terminal amine and any lysines in the
protein) whereas 125I was coupled to tyrosine. The similarity of the
amine-modiﬁed proteins made us hypothesize that the functional
behavior of the differently labeled Fab fragments would relatemore to
the functional group used for labeling, rather than the label per se,
since lysines are not as common in CDRs as tyrosines [27]. However, as
seen in Figs. 3 and 4a, the 125I- and FITC-labeled fragments both
produced more biphasic interactions, whereas the 111In-labeled
fragment generated a more monophasic interaction (statisticallysigniﬁcant in A431 cells, but with the same trend in H314 and SCC-25
cells). It is possible that the large size or lipophilicity of FITC, or the
temperature during labeling (37°C, compared to room temperature
for 111In and 125I) may have inﬂuenced the binding characteristics of
this conjugate. Lipophilicity is known to mediate aggregation [25,26],
and consequently a plausible explanation could be that the low
afﬁnity population for the FITC-Fab may be due to aggregation caused
by hydrophobic effects. This is supported by the aggregation analysis
results, where FITC-Fab clearly displayed a higher presence of
aggregates and less monomers compared to 111In-Fab.
Another factor that should be taken into account is that 111In is a
radiometal. Radiometals are known residualizing labels, and if
internalized the radiolabel will be retained for a long time in the
cells, in contrast to e.g. 125I, which will be degraded and excreted
from the cells. An alternative explanation for the slower dissociation
of 111In-Fab could thus be possible internalization of the conjugate.
However, previous studies of CD44v6 have shown that CD44v6 is
generally not an internalizing receptor [20,29]. Moreover, the
experiments in this report were made in room temperature in
order to minimize any potential internalization of the conjugates.
Consequently, we hypothesize that the biphasic interaction patterns
seen in this study were mainly caused by one "original" high-afﬁnity
Fig. 4. Weight (a), KD (b), dissociation rate constant kd (c), and association rate constant ka (d) of the high afﬁnity peak of Fab-fragment AbD15179 labeled with FITC (diagonal
stripes), 125I (horisontal stripes), and 111In (white) in the SCC cell lines SCC-25 (black bars), H314 (dark gray) and A431 (light gray). Analyses of variance was made using One-way
ANOVA followed by Tukey's Multiple Comparison Test, and was considered signiﬁcant if P b 0.05. Error bars = standard deviation (SD). N N 3. While weight and KD of the high
afﬁnity peak varied more between labels than between cell lines, association rate constant (ka) and dissociation rate constant (kd) were more cell line dependent. Results
demonstrated a signiﬁcantly higher contribution from the high afﬁnity peak for 111In-Fab compared to 125I-Fab in H314 and A431 cells, whereas the choice of cell line did not seem to
inﬂuence the weight of the populations (a). Also KD of the high afﬁnity peak appeared to be mainly conjugate dependent. A trend of higher KD for 111In-Fab and lower for 125I-Fab
could be seen for all three cell lines, although this was only statistically signiﬁcant in SCC-25 cells (b). When also considering ka and kd, another pattern more dependent on cell line
than on choice of conjugate appeared. For 111In-Fab and 125I-Fab conjugates, the SCC-25 cell line demonstrated a signiﬁcantly increased dissociation rate constant (kd) compared to
the other two cell lines. The same trend could be seen for the association rate constant (ka), but was not statistically signiﬁcant (c and d).
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interaction properties of some of the fragments during the labeling
process (e.g. damaged or aggregated conjugates). This low-afﬁnity
population would not have been detected in a standard immunoreac-
tivity assay or in an endpoint binding assay. In such assays, themajority
of the low afﬁnity population would be washed away, and what is left
of it at detection would contribute to an average afﬁnity value located
between the two populations. Interaction Map has previously been
used to characterize how the binding of a speciﬁc conjugate to cell
receptors can be altered in different settings (e.g. starvation, receptor
dimerization etc.) [4]. In this study, we have shown that Interaction
Map also can be used to assess binding properties of a labeled
compound, by detecting a second population of low-afﬁnity binders
and monitoring how this weakly binding population is decreased or
increased when labeling conditions are modiﬁed. Thus, real-time
bindingmeasurements togetherwith InteractionMap can be important
techniques also for quality control of labeled conjugates, as it identiﬁes
heterogeneous interactions and deﬁnes how much each interaction
component contributes to the binding.
One important question is if improved characterization of protein
interactions can be used to help select the most suitable protein or
labeling approach for in vivo imaging. There are of course many
differences between the in vitro and in vivo settings, and properties
such as blood clearance and normal tissue uptake cannot yet be
adequately assessed with in vitro techniques. However, knowledge of
binding characteristics (e.g. on-rate, off-rate, afﬁnity), quality of
labeled conjugate (e.g. occurrence/increase of low-afﬁnity popula-
tions), and interaction differences between standard labeling
methods, will aid this decision and may contribute to saving time,money and animals. Generally, for the purpose of medical imaging,
molecular interactions with KD in the nanomolar region or stronger
tend to provide good images. However, a conjugate with slower
dissociation rate, such as the 111In-labeled compound, will most likely
provide better imaging contrasts in vivo compared to a conjugate with
faster dissociation rate, like the 125I-labeled compound, since a longer
lasting signal in the tumor may enable a better tumor-to-background
contrast. A fast association rate of conjugate binding might further-
more enable satisfactory images in a shorter time-frame. In our case, a
high proportion of high afﬁnity binders combined with a high
association rate and a slow dissociation rate would be ideal. Hence,
based on the available data, the 111In-Fab would seem optimal for
future in vivo studies using tumor-bearing mice, especially in
combination with the A431 cell line. However, this remains to be
veriﬁed in future studies.
The fact that different cell lines promoted different interactions is
also important to consider in a clinical setting. The variability across
different cell lines reﬂects the variability one can expect in a patient
population. For instance, a tumor with the slower binding behavior
will probably retain a larger amount of radioactive tracer than a tumor
with fast binding behavior. Hence, when imaged using the same
clinical protocol, the tumor with a faster conjugate dissociation will
most likely inaccurately appear smaller than the slower one, since less
radioactivity is retained on the fast one at the time of imaging.
To conclude; in this study we have assessed for the ﬁrst time how
cell-based real-time measurements and Interaction Map analysis can
be used to demonstrate how, and in what way, antibody–antigen
interactions vary with different labeling techniques and cell lines. We
have ﬁrst shown how chloramine T exposure to Fab-fragments
147J. Stenberg et al. / Nuclear Medicine and Biology 41 (2014) 140–147AbD15179 increases a subpopulation of conjugates with lower
afﬁnity, displaying the same association rate as the high afﬁnity
population, but with a faster dissociation rate. Furthermore, we have
demonstrated how kinetic properties vary with labeling methods,
where the altered ratios of high- and low-afﬁnity populations are
responsible for the difference in kinetic properties, rather than a
general shift in afﬁnity for the entire conjugate population. Thus, for
molecular imaging, or any other application where the targeting
molecule is labeled, this study highlights the relevance to characterize
the labeled conjugate rather than the original protein. We have also
characterized for the ﬁrst time how AbD15179 interacts with different
SCC cells, and how this interaction is CD44v6 speciﬁc but display cell
line dependent kinetic properties, possibly due to different CD44v6-
containing isoforms on the cells. Care is advised when characterizing
molecular interactions on living cells and it appears important to refer
to the measured afﬁnity and kinetics for a protein–receptor
interaction together with the hosting cell line. This also emphasizes
the importance of characterizing molecular interactions on a panel of
cell lines rather than on a single cell line.
Results in this study may be utilized for further characterizations
of speciﬁc CD44v6-containing isoforms, CD44v6-expressing subpop-
ulations, as well as for labeling optimizations and quality control of
labeled conjugates, and may contribute to further insight into aspects
to consider when developing targeted agents for imaging purposes.
Furthermore, there is no doubt that detailed interaction analyses are
important in a clinical setting, where each individual tumor may
create different kinetic proﬁles for the same conjugate. We have
shown that with the advent of precise analytical tools, improved
characterization of the interactions utilized for imaging is now
possible. However, a suitable approach to implement this in a clinical
setting in order to provide better diagnoses and personalized
medicine remains to be determined.
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